Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Visilizumab in Glucocorticoid-Refractory Acute Graft-Versus-Host Disease
NCT00032279Phase 2Unknown
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2002
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of visilizumab in graft-versus-host disease (GVHD), sponsored by Fred Hutchinson Cancer Center. Status: unknown.
02
Drugs
visilizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT00032279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00032279.